Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
People
Search
DE
Back
Abstract lecture
AL009
Ubrogepant for the acute treatment of migraine when administered during the prodrome (premonitory phase): results from a phase 3, randomized, double-blind, placebo-controlled, crossover study
Peter J. Goadsby
London, GB
Appointment
Date:
07/12/2023
Time:
11:05
–
11:15
Talk time:
8 Min.
Discussion time:
2 Min.
Location / Stream:
Plenary hall
Session
ScS 3 | Aura and premonitory symptoms
Topic
Aura and premonitory symptoms
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy